23.06.2016 Views

VACCINE

CnXHqJ

CnXHqJ

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

“Because the product is itself a virus,<br />

traditional viral clearance steps are generally not included in the manufacturing process ...”<br />

PDA Journal Of Pharmaceutical Science And Technology • November 2011<br />

Application of Risk Assessments<br />

in the Design of the Overall Viral Control Strategy Used<br />

during the Manufacture and Testing of Live Virus Vaccines<br />

Author information<br />

Pennathur S.<br />

MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878<br />

Abstract<br />

CONFERENCE PROCEEDING<br />

Proceedings of the PDA/FDA Adventitious Viruses in Biologics: Detection and Mitigation Strategies Workshop in<br />

Bethesda, MD, USA; December 1-3, 2010 Guest Editors: Arifa Khan (Bethesda, MD), Patricia Hughes (Bethesda,<br />

MD) and Michael Wiebe (San Francisco, CA) It is important to include a risk assessment process in the overall<br />

viral control strategy used during the manufacture and testing of live virus vaccines. Because the product is itself<br />

a virus, traditional viral clearance steps are generally not included in the manufacturing process, and there is<br />

normally no inactivation step in the manufacturing process either. The risk assessment is therefore necessary to<br />

identify potential sources for entry of adventitious agents into the vaccine, and to develop a strategy to minimize<br />

or eliminate the sources through which adventitious agents can enter the vaccine. The risk assessment can also be<br />

used to tailor the biosafety testing that is performed on raw materials, vaccine seeds, vaccine bulk materials, and<br />

final product. Biosafety testing is normally designed to ensure the detection of both known and unknown adventitious<br />

agents, but the results of the risk assessment can be used to put in place a biosafety testing strategy designed<br />

to maximize the detection of an adventitious agent that is potentially likely to be present in the vaccine. The risk<br />

assessment therefore enables the development of a comprehensive viral control strategy and provides a higher<br />

level of assurance that the vaccine will be free from contamination by adventitious agents.<br />

http://www.ncbi.nlm.nih.gov/pubmed/22294607

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!